3 Indian Export Stocks Retail Investors May Be Researching After India GDP Growth Hit 7.8%
India just posted Q1 GDP growth of 7.8%, even as inflation pressures, a weaker rupee and questions around data quality keep investors on edge. Export oriented companies linked to this growth mix of fiscal support, softer rates and stronger overseas demand may see sharply different outcomes. This article walks through three stocks from an export focused screener that appear especially exposed to these cross currents right now.
The stocks discussed below are just a sample from this export focused idea, and the full screen surfaced 66 more listed Indian companies with international angles that are not covered here but have similarly detailed stories attached to them. If you want to go straight to the full list and create your own shortlist, use the India export-oriented equities screener to identify, filter and analyze the export oriented equities that best match your thesis.
Alivus Life Sciences (NSEI:ALIVUS)
Overview: Alivus Life Sciences is an export focused API manufacturer that supplies a wide range of complex active ingredients for cardiovascular, central nervous system, diabetes, oncology and urology treatments to customers across the US, Europe, Japan and other major pharma markets. The company also runs a contract development and manufacturing platform that helps global drug companies design, scale and reliably source APIs from India.
Operations: Alivus Life Sciences currently generates its ₹25,904 million revenue entirely from its Active Pharmaceutical Ingredient business.
Market Cap: ₹174.0 billion
For an investor looking at India’s export story, Alivus Life Sciences is a direct way to gain exposure to global pharma outsourcing and a weaker rupee through a pure API platform with broad therapeutic coverage. The company couples export driven revenue with high net margins and governance that includes a largely independent board, yet leans heavily on external debt funding, which can magnify currency and refinancing risk. Dividend payments have been irregular, so the appeal is more about compounding earnings than steady income. With forecasts pointing to double digit earnings expansion and a P/E that screens below the wider pharma group, the key question is how much of this export and outsourcing potential is already reflected in the valuation and how much may still be underappreciated by the market.
Alivus Life Sciences combines export-heavy API revenue with high net margins and board independence, yet relies on debt and irregular dividends. Get the full story with the 4 key rewards and 1 important warning sign
Gland Pharma (NSEI:GLAND)
Overview: Gland Pharma is an India based injectables specialist that manufactures and sells complex sterile formulations to hospitals and pharma partners across the US, Europe and other regulated markets, tying it closely to the export focused healthcare demand that underpins this screener. Its portfolio spans high value generics and contract development work for global clients, giving investors exposure to international drug spending and India’s cost advantage in pharma manufacturing.
Operations: Gland Pharma generates about ₹67.3 billion in revenue from its pharmaceuticals business, with exports to the USA, Europe and the Rest of the World contributing the majority of sales and India a smaller share.
Market Cap: ₹473.2 billion
Gland Pharma is the kind of export heavy story many investors look for when India’s rupee is weaker and global healthcare demand is firm, with injectables, GLP 1 related capacity and CDMO deals tying the company directly to overseas clients. Stronger recent earnings, USFDA approvals and new long term manufacturing agreements point to a business that is adding new product and customer layers. However, revenue concentration in the US and select molecules, regulatory scrutiny in regulated markets and a rich valuation create real risk if execution slips. In addition, management changes and ongoing capex contribute to a business where the upside of global expansion is clear, while the full balance of rewards and pressures is worth understanding in more detail.
Gland Pharma’s export momentum, GLP 1 exposure and CDMO wins could be telling a different story to what the headline valuation suggests. Use the 2 key rewards and 1 important warning sign to see what might be hiding in plain sight.
eClerx Services (NSEI:ECLERX)
Overview: eClerx Services is an India based IT and business process management exporter that runs data, analytics and digital operations for clients across North America, the UK, Europe and Asia Pacific, giving investors direct exposure to global offshoring and rupee sensitive revenue. The company handles everything from customer support and digital marketing to compliance, risk analytics and trading support for sectors such as financial services, telecom, retail and software.
Operations: eClerx Services generates about ₹43,348 million in revenue from its Data Management, Analytics Solutions and Process Outsourcing Services division.
Market Cap: ₹184.5 billion
eClerx Services is closely tied to the India export oriented equities theme because almost all of its work and cash flows come from overseas clients who pay in foreign currencies, so rupee depreciation and offshoring demand can feed directly into revenue and margins. Recent results show revenue and profit supported by return on equity near 28% and a focus on higher value analytics and automation for regulated sectors like banking and financial services. On the other hand, heavy exposure to US and European spending, rising wage costs and pressure from AI driven automation could affect growth or pricing power if execution slips. For investors tracking export led IT earnings, a key consideration is how sustainable this quality and growth mix is and what factors might change it.
eClerx Services appears to be an export engine that is quietly compounding, with high value analytics and automation work supporting quality metrics. Read the analyst forecasts for eClerx Services to see what might be accelerating or at risk next.
Seeking Fresh Alternatives Before Others?
Markets move fast and the strongest themes often break out while attention is elsewhere. Scan these fresh ideas before the momentum is fully caught by the crowd and act now.
- Target income streams by checking companies in the 375 dividend fortresses before yields change as more investors focus on the same cash flow stories.
- Explore potential automation leaders by reviewing the curated 36 robotics and automation stocks while these enablers of productivity gains are still relatively under the radar.
- Consider infrastructure-related opportunities by examining the focused 38 power grid technology and infrastructure stocks ahead of possible large-scale grid modernisation activity.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com